Irish Journal of Medical Science (1971 -)

, Volume 184, Issue 1, pp 23–30

α1-Blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Review Article

Abstract

Background

α1-Blockers have been widely used in the conservative management of acute urinary retention (AUR).

Aims

To compare the efficacy and safety of α1-blockers in male patients with AUR secondary to benign prostatic hyperplasia (BPH).

Methods

Electronic searches on PubMed/MEDLINE, EMBASE and the Cochrane Library were performed to identify all published randomized controlled trials (RCTs) and controlled clinical trials (CCTs) of α1-blockers for the treatment of AUR. Relevant reviews and reference lists of included studies were explored.

Results

Nine studies involving a total of 1051 men were enrolled in this review. Compared to 38.9 % (161/414) in control groups, 56.8 % (362/637) of patients receiving α1-blockers had a successful trial without catheter (TWOC). Meta-analysis demonstrated that α1-blockers have a substantial effect on the successful resumption of micturition after TWOC (RR = 1.45, 95 % CI 1.20–1.75, P = 0.0001). In the subsequent phase, the outcomes across studies indicated that α1-blockers may provide little benefit to maintain the satisfactory voiding without AUR recurrence or BPH surgery in a long-term follow-up. α1-Blockers were generally low and well tolerated in both phases.

Conclusions

In conclusion, α1-blockers provide substantial benefit in increasing a satisfactory micturition within 24 h after TWOC for men with AUR due to BPH, even though the long-term effectiveness remains uncertain.

Keywords

Acute urinary retention Benign prostatic hyperplasia Alpha-blockers Trial without catheter Meta-analysis 

Supplementary material

11845_2014_1094_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 14 kb)
11845_2014_1094_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 16 kb)
11845_2014_1094_MOESM3_ESM.eps (1.2 mb)
Supplementary material 3 (EPS 1263 kb)
11845_2014_1094_MOESM4_ESM.eps (1.2 mb)
Supplementary material 4 (EPS 1256 kb)
11845_2014_1094_MOESM5_ESM.eps (1.6 mb)
Supplementary material 5 (EPS 1617 kb)
11845_2014_1094_MOESM6_ESM.eps (1.6 mb)
Supplementary material 6 (EPS 1600 kb)
11845_2014_1094_MOESM7_ESM.docx (15 kb)
Supplementary material 7 (DOCX 15 kb)
11845_2014_1094_MOESM8_ESM.eps (1.1 mb)
Supplementary material 8 (EPS 1126 kb)

References

  1. 1.
    Hartung R (2004) Do alpha-blockers prevent the occurrence of acute urinary retention? Eur Urol 39(Suppl. 6):13–18CrossRefGoogle Scholar
  2. 2.
    Schulman CC (2001) Long-term aspects of medical treatment of BPH. Eur Urol 40(Suppl. 3):8–12CrossRefPubMedGoogle Scholar
  3. 3.
    Jacobsen SJ, Jacobson DJ, Girman CJ et al (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158(2):481–487CrossRefPubMedGoogle Scholar
  4. 4.
    Rendell S (2011) Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1. Alpha-blockers increase the chances of a successful trial without catheter after acute urinary retention. Emerg Med J 28(2):161–165PubMedGoogle Scholar
  5. 5.
    Emberton M, Fitzpatrick JM (2008) The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int 101(s3):27–32CrossRefPubMedGoogle Scholar
  6. 6.
    Murray K, Massey A, Feneley R (1984) Acute urinary retention–a urodynamic assessment. BJU Int 56(5):468Google Scholar
  7. 7.
    Taube M, Gajraj H (1989) Trial without catheter following acute retention of urine. BJU Int 63(2):180–182CrossRefGoogle Scholar
  8. 8.
    Pickard R, Emberton M, Neal DE (1998) The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. BJU Int 81(5):712–720CrossRefGoogle Scholar
  9. 9.
    Altarac S (2006) Alpha-adrenergic blockers as a support in the treatment of acute urinary retention. Molecular medicine 128(7–8):233Google Scholar
  10. 10.
    McNeill SA (2004) The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 45(3):325–332CrossRefGoogle Scholar
  11. 11.
    Higgins J, Altman D and Sterne J e (2011) Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011), The Cochrane Collaboration Available from www.cochrane-handbook.org
  12. 12.
    Schünemann H, Oxman A, Vist G et al (2011) Interpreting results and drawing conclusions. In: Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011), The Cochrane Collaboration Available from www.cochrane-handbook.org
  13. 13.
    Holger Schünemann, Jan Brozek, and Andrew Oxman (2009) GRADEpro [Computer program] Version 3.6 for WindowsGoogle Scholar
  14. 14.
    Egger M, Smith G D and Altman D (2008), Systematic reviews in health care: meta-analysis in context, Wiley comGoogle Scholar
  15. 15.
    Mariappan P, Brown DJ, McNeill AS (2007) Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol 178(2):573–577 discussion 577CrossRefPubMedGoogle Scholar
  16. 16.
    Bhomi KK, Bhattachan CL (2011) Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia. Nepal Med Coll J 13(3):178–181PubMedGoogle Scholar
  17. 17.
    McNeill SA, Hargreave TB (2004) Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 171(6 Pt 1):2316–2320CrossRefPubMedGoogle Scholar
  18. 18.
    Perepanova TS, Kamalov AA, Siniukhin VN et al (2001) Doksazozin “Cardura” in acute urinary retention caused by benign prostatic hyperplasia. Urologiia 3:18–20PubMedGoogle Scholar
  19. 19.
    Hua LX, Wu HF, Sui YG et al (2003) Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention. Zhonghua Nan Ke Xue 9(7):510–511PubMedGoogle Scholar
  20. 20.
    Lorente GJA, Canis SD, Arango TO et al (2004) Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect. Actas Urol Esp 28(1):32–37CrossRefGoogle Scholar
  21. 21.
    Elbendary M, El-Gamal O M, Soliman M G et al (2013) Role of combined use of ketoconazole and tamsulosin in management of acute urinary retention due to benign prostatic obstruction (a randomized controlled trial). Prostate Cancer Prostatic DisGoogle Scholar
  22. 22.
    Pourreza F, Mokhtari G, Falahatkar S et al (2012) Assessment the addition of sildenafil to alpha-blocker (tamsulosine) in the management of acute urinary retention due to benign prostatic hyperplasia. Urology 80(3):S76–S77Google Scholar
  23. 23.
    Annemans L, Cleemput I, Lamotte M et al (2005) The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU Int 96(4):566–571CrossRefPubMedGoogle Scholar
  24. 24.
    McNeill SA, Rizvi S, Byrne DJ (2004) Prostate size influences the outcome after presenting with acute urinary retention. BJU Int 94(4):559–562CrossRefPubMedGoogle Scholar
  25. 25.
    McNeill SA, Daruwala PD, Mitchell ID et al (1999) Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int 84(6):622–627CrossRefPubMedGoogle Scholar
  26. 26.
    Agrawal MS, Yadav A, Yadav H et al (2009) A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol 25(4):474–478CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Kumar S, Tiwari DP, Ganesamoni R et al (2013) Prospective Randomized Placebo-controlled Study to Assess the Safety and Efficacy of Silodosin in the Management of Acute Urinary Retention. Urology 82(1):171–175CrossRefPubMedGoogle Scholar
  28. 28.
    Lucas MG, Stephenson TP, Nargund V (2005) Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 95(3):354–357CrossRefPubMedGoogle Scholar
  29. 29.
    Maldonado-Avila M, Manzanilla-Garcia H A, Sierra-Ramirez J A et al (2013) A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth. Int Urol NephrolGoogle Scholar
  30. 30.
    McNeill SA, Hargreave TB, Roehrborn CG (2005) Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 65(1):83–89 discussion 89–90CrossRefPubMedGoogle Scholar
  31. 31.
    Prieto L, Romero J, Lopez C et al (2008) Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 81(1):66–71CrossRefPubMedGoogle Scholar
  32. 32.
    Shah T, Palit V, Biyani S et al (2002) Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 42(4):329–332 discussion 332CrossRefPubMedGoogle Scholar
  33. 33.
    Tiong HY, Tibung MJ, Macalalag M et al (2009) Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urol Int 83(1):44–48CrossRefPubMedGoogle Scholar
  34. 34.
    Higgins J, Deeks J, and Altman D e (2011) Special topics in statistics. In: Higgins JPT, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], The Cochrane Collaboration Available from www.cochrane-handbook.org
  35. 35.
    Kuritzky L (2005) Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Compr Ther 31(3):194–208CrossRefPubMedGoogle Scholar
  36. 36.
    Djavan B, Shariat S, Omar M et al (1998) Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention (AUR). Eur Urol 33(Suppl 1):110Google Scholar
  37. 37.
    Lo KL, Chan MC, Wong A et al (2010) Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Int Urol Nephrol 42(1):7–12CrossRefPubMedGoogle Scholar
  38. 38.
    Zeif HJ, Subramonian K (2009) Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database Syst Rev (4):CD006744. doi:10.1002/14651858.CD006744.pub2
  39. 39.
    Sterne J Egger M and Moher D e (2011) Addressing reporting biases. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], The Cochrane Collaboration Available from www.cochrane-handbook.org

Copyright information

© Royal Academy of Medicine in Ireland 2014

Authors and Affiliations

  1. 1.Minimally Invasive Urology CenterShandong Provincial Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations